The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Clinical Cancer Research|2015Cited by 18
THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITIONEmmanouil Spanoudakis, Ιoannis Kotsianidis, Menelaos Papoutselis et al.|Mediterranean Journal of Hematology and Infectious Diseases|2018Cited by 9
Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with AzacitidineAthanasios Tasis, Ioannis Mitroulis, Nikos E. Papaioannou et al.|Cancer Research Communications|2024Cited by 9
Data from Single-Cell Analysis of Bone Marrow CD8<sup>+</sup> T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with AzacitidineAthanasios Tasis, Ioannis Mitroulis, Nikos E. Papaioannou et al.|Unknown|2024Cited by 1
CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling BiosignatureEleftheria Lamprianidou, Ιoannis Kotsianidis, Constantinos Tsatalas et al.|Blood|2014Cited by 1